FDA Approved: IMPAVIDO — Supplemental Application (Profounda, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for IMPAVIDO (miltefosine) filed by Profounda, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-kala-azar Dermal Leishmaniasis
• Visceral Leishmaniasis

Drugs mentioned

• Impavido (miltefosine)

Snippet

SUPPL AP for IMPAVIDO (MILTEFOSINE)